Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

4/27/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Juluca

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Rilpivirin Testmiljö

Rilpivirin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Referensgruppen för antiviral terapi (RAV). Profylax och behandling av HIV-infektion vid graviditet, 2017. www.sls.se/rav/. Hämtat 2017-11-28.

  1. Referensgruppen för antiviral terapi (RAV). Profylax och behandling av HIV-infektion vid graviditet, 2017. www.sls.se/rav/. Hämtat 2017-11-28.
2 2
2 2

Dolutegravir Testmiljö

Dolutegravir

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. EMA. Tivicay. CHMP Assessment report; 2013-11-21 http://goo.gl/S3dtjH

  2. Lewis JM, Railton E, Riordan A, Khoo S, Chaponda M. Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS. 2016;30:1313-5.

  3. Ikumi NM, Anumba D, Matjila M. Pharmacokinetics and placental transfer of dolutegravir in pregnancy. J Antimicrob Chemother. 2021.

  4. EMA. New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir. EMA [www]. [updated 2018-05-18, cited 2022-04-12].

  5. Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019;381(9):827-840.

  6. Raesima MM, Ogbuabo CM, Thomas V, Forhan SE, Gokatweng G, Dintwa E et al. Dolutegravir Use at Conception - Additional Surveillance Data from Botswana. N Engl J Med. 2019;381(9):885-887.

  7. Pereira GFM, Kim A, Jalil EM, Fernandes Fonseca F, Shepherd BE, Veloso VG et al. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021;8(1):e33-e41.

  8. Vannappagari V, Thorne C, for APR and EPPICC. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir. J Acquir Immune Defic Syndr. 2019;81(4):371-378.

  9. Money D, Lee T, O'Brien C, Brophy J, Bitnun A, Kakkar F et al. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study. BJOG. 2019;126(11):1338-1345.

  10. WHO. UPDATE OF RECOMMENDATIONS ON FIRST- AND SECOND-LINE ANTIRETROVIRAL REGIMENS. WHO [www]. [updated 2019-07-01, cited 2022-04-12].

  11. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission . Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Clinicalinfohivgov [www]. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission . [updated 2022-03-17, cited 2022-04-12].

  1. EMA. Tivicay. CHMP Assessment report; 2013-11-21 http://goo.gl/S3dtjH
  2. Lewis JM, Railton E, Riordan A, Khoo S, Chaponda M. Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS. 2016;30:1313-5.
  3. Ikumi NM, Anumba D, Matjila M. Pharmacokinetics and placental transfer of dolutegravir in pregnancy. J Antimicrob Chemother. 2021.
  4. EMA. New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir. EMA [www]. [updated 2018-05-18, cited 2022-04-12].
  5. Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019;381(9):827-840.
  6. Raesima MM, Ogbuabo CM, Thomas V, Forhan SE, Gokatweng G, Dintwa E et al. Dolutegravir Use at Conception - Additional Surveillance Data from Botswana. N Engl J Med. 2019;381(9):885-887.
  7. Pereira GFM, Kim A, Jalil EM, Fernandes Fonseca F, Shepherd BE, Veloso VG et al. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021;8(1):e33-e41.
  8. Vannappagari V, Thorne C, for APR and EPPICC. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir. J Acquir Immune Defic Syndr. 2019;81(4):371-378.
  9. Money D, Lee T, O'Brien C, Brophy J, Bitnun A, Kakkar F et al. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study. BJOG. 2019;126(11):1338-1345.
  10. WHO. UPDATE OF RECOMMENDATIONS ON FIRST- AND SECOND-LINE ANTIRETROVIRAL REGIMENS. WHO [www]. [updated 2019-07-01, cited 2022-04-12].
  11. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission . Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Clinicalinfohivgov [www]. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission . [updated 2022-03-17, cited 2022-04-12].